Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
Information source: New York State Psychiatric Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Borderline Personality Disorder
Intervention: Fluoxetine (Drug); Dialectical Behavior Therapy (Behavioral); Supportive psychotherapy (Behavioral)
Phase: Phase 4
Status: Completed
Sponsored by: New York State Psychiatric Institute Official(s) and/or principal investigator(s): Barbara Stanley, PhD, Principal Investigator, Affiliation: Research Foundation for Mental Hygiene/Columbia University
Summary
This study will determine whether dialectical behavior therapy and fluoxetine are more
effective combined or alone in treating people with borderline personality disorder.
Clinical Details
Official title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Decrease in self injury (suicide-related behavior and NSSI)
Secondary outcome: suicide ideation, depression and impulsivity
Detailed description:
Borderline personality disorder (BPD) can be a serious and very complex condition. BPD
affects 2% to 3% of the population and is more commonly diagnosed in young women. BPD is
characterized by mood swings, impulsive behavior, difficulty controlling emotions, and
acting out inappropriately either through self-harm or attempts of suicide. Other illnesses
such as depression and anxiety are also very common in people diagnosed with BPD. Various
treatments exist that aim to reduce self-harm and suicide among people with BPD. Dialectical
behavior therapy (DBT), an outpatient behavioral therapy shown to help self-injurious
patients with BPD, has become a popular treatment. Another useful treatment, the
antidepressant fluoxetine, can help to regulate mood and diminish suicidal or
self-destructive urges. Although combination treatments of DBT and fluoxetine are common,
little research has been conducted on the effectiveness of this kind of combined treatment.
The purpose of this study is to determine whether DBT and fluoxetine are more effective
combined or alone in treating people with BPD.
All participants in this double-blind study will receive a psychiatric and medication
evaluation prior to starting treatment. Participants taking psychiatric medications prior to
the study will be slowly withdrawn from the medications over a period of 2 to 6 weeks.
Psychological interviews and self-report questionnaires will be administered, taking
approximately 5 to 10 hours to complete. Once all preliminary interviews and evaluations
have been completed, each participant will be randomly assigned to one of the four following
treatment groups:
- Group 1 will receive DBT and fluoxetine (Prozac). DBT teaches patients new skills to
replace old coping strategies such as suicide attempts and self-injury. Participants
will work with an individual therapist for 1 hour a week to learn these new skills.
This group will also be expected to keep a weekly diary that will discuss their current
mood; suicidal and self-harming urges; and possible use of medications, drugs, and
alcohol. Once a week participants will engage in a 90-minute skills training group to
review the skills learned during therapy. Homework will be assigned between sessions to
review these new strategies and skills. Participants will meet regularly with a
psychiatrist to receive fluoxetine, discuss any side effects, and adjust dosage if
necessary.
- Group 2 participants will receive DBT and placebo medication.
- Group 3 participants will receive supportive therapy and fluoxetine. Supportive therapy
is nondirective and focuses on strengths, coping abilities, and current areas of
difficulty in life in an unstructured format. Participants in this group will meet with
an individual therapist each week for 50 minutes. Patients will also be assigned to a
psychiatrist to receive fluoxetine every other week.
- Group 4 participants will receive supportive psychotherapy and placebo medication.
All patients participating in this study will continue treatment for 12 months and will be
evaluated bimonthly. After 12 months, participants will undergo neuropsychological testing
to identify any changes that occurred over the last year. The clinical status of each
participant will also be assessed at 18 and 24 months.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets criteria for DSM-IV diagnosis of borderline personality disorder
- History of at least one suicide attempt or self-mutilation episode 12 months prior to
study entry
- Experiences continued urges to self-mutilate or attempt suicide
- Stable living situation
- Use of effective birth control if sexually active
- Clinically stable enough to tolerate placebo condition
- Not participating in other forms of treatment during the study
Exclusion Criteria:
- Any current organic mental syndromes, lifetime schizophrenic or bipolar disorders,
psychotic disorders, or mental retardation
- Inability to complete psychiatric interview due to lack of cooperation or lack of
comprehension
- Unable to tolerate fluoxetine or DBT
- Currently receiving treatment for an acute medical illness or other debilitating
problem, including substance abuse or anorexia nervosa
- History of major depression lasting more than 3 months
- Current Hamilton depression score above 22 and not receiving treatment
- Pregnant or breastfeeding
Locations and Contacts
New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information
Starting date: March 2001
Last updated: September 25, 2013
|